Sermorelin is the shortest synthetic GHRH peptide with full biological activity — a 29-amino-acid analog of human GHRH (Prakash & Goa, PMID 18031173). Its longest trial track record is in the pediatric growth hormone deficiency setting, where it has been used diagnostically and therapeutically for decades. Adult use is largely off-label (US) or compounded; the safety dataset relevant to adult anti-aging community use is informed by pediatric trial data and self-reports.
Research-context information only.Sermorelin is the active ingredient in FDA-approved products for pediatric idiopathic growth hormone deficiency; compounded forms for adult anti-aging or anabolic use are not FDA-approved. Protocols, doses, and reactions reported below come from clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
This article summarizes the trial-reported adverse events, separates the pediatric-indication trial data from the community-source adult anti-aging picture, and walks through the dose-pause patterns described in research and community sources.
Trial-Reported Adverse Events
From the pediatric GHD program (reviewed by Prakash & Goa, PMID 18031173) using 30 mcg/kg/day subcutaneous:
The pediatric dataset's adverse-event picture is described as well-tolerated. The trial's dose was substantially below adult community-reported anti-aging doses on a per-kg basis, but the absolute mass differs based on body weight.
The Walker adult-onset growth hormone insufficiency review (referenced in mechanism literature) describes a similar safety pattern in small adult studies — favorable, with mild events dominated by injection-site reactions and brief facial flushing.
Self-Reported Community Adverse Events for Adult Use
Note on labeling: the events below come from r/peptides, r/PeptideTherapy, and community forums for adult subcutaneous sermorelin use, typically at doses substantially higher than pediatric trial protocols.
Injection-site reactions
The most consistent community feedback. Mild redness, itching, or a small welt at the subcutaneous injection site, typically lasting under 24 hours. Self-reported community sources describe rotating sites and warming the vial to room temperature as factors that reduce reaction frequency.
Brief facial flushing within 10-20 minutes
Community sources commonly describe brief warmth and visible flush after subcutaneous injection. The pattern aligns with what pediatric IV-administration data documented.
Fluid retention or "puffy" feel
Self-reported community timelines describe mild fluid retention — particularly noticeable in the face and hands — during the first 2-4 weeks at higher adult doses. The pattern is dose-dependent and resolves with dose reduction.
Hand tingling
Community reports cluster around transient hand tingling at higher doses, attributed by community sources to GH-induced fluid retention causing median-nerve compression. This is a documented GH-pharmacology pattern (see tesamorelin side effects for the trial-grade version).
Vivid dreams or sleep changes
Most consistent community feedback for evening administration is vivid dreams or restless sleep in the first week.
Less Commonly Reported Events
These appear sparsely in community data.
Increased appetite — sparse; community sources commonly attribute this to broader GH-axis effects.
Lightheadedness post-injection — sparse, attributed to vasodilatory effects.
Joint achiness — uncommon at typical doses; attributed by community sources to fluid-retention effects on joint capsules.
IGF-1 Monitoring Patterns
Community sources for adult sermorelin use commonly describe IGF-1 monitoring at baseline, 6-8 weeks, and 16-24 weeks of use. Self-reported community sources describe dose reduction when IGF-1 exceeds the lab's upper reference range. The community pattern parallels FDA labeling practice for the related tesamorelin product.
Dose-Response Patterns
The pediatric trial dose was 30 mcg/kg/day subcutaneous. Adult community-reported anti-aging doses cluster around 200-500 mcg per dose, daily for 4-8 weeks, then maintenance. Self-reported community sources describe injection-site reactions and fluid retention scaling with daily dose; serious events remain rare at typical adult-use doses.
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
30ml from $18.75 · Ships fast · Code thepeptidecatalog
Dose-Pause and Discontinuation Patterns
Pediatric trial protocols paused dosing for protocol-defined adverse events. Community sources describe two patterns. Pause-and-resume — short breaks when fluid retention or hand tingling becomes intrusive. Dose-cycling — community sources commonly describe 8-12 week on / 4 week off cycles, citing IGF-1 normalization during off-cycles.
Core Supplies for This Protocol
The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking.
Pediatric and adult sermorelin trials reported transient facial flushing and injection-site pain as the most common adverse events (Prakash & Goa review, PMID 18031173). Serious adverse events were rare across the available dataset.
Does sermorelin cause water retention or hand tingling?
Self-reported community data describes mild fluid retention and occasional hand tingling at higher doses — the same pattern documented for other GH-axis stimulants. The published trial dataset focused largely on pediatric growth and did not characterize these patterns in detail.
Is sermorelin FDA-approved?
The active ingredient sermorelin is the active ingredient in FDA-approved products for pediatric idiopathic growth hormone deficiency. Compounded forms for adult anti-aging or anabolic use are not FDA-approved. The trial-grade safety record comes from the pediatric indication.
Does sermorelin elevate IGF-1?
Yes. GHRH-pathway agonism produces dose-proportional GH and IGF-1 elevation. The pediatric trial data documented sustained height-velocity increases over 12+ months attributable to this elevation. Adult community sources commonly describe IGF-1 monitoring at 6-8 weeks of use.
When do trial protocols and community sources describe stopping sermorelin?
Pediatric trials paused dosing for protocol-defined adverse events; permanent discontinuation was uncommon. Community sources describe dose reduction or pause when injection-site reactions persist, when fluid retention is intrusive, or when IGF-1 exceeds the lab's upper reference range.
For educational and research purposes only. This is not medical advice. Compounded sermorelin for adult anti-aging use is not FDA-approved. Consult a healthcare provider before use.
